Johnson and Johnson buys FemRx in expansion of women's health business
This article was originally published in Clinica
Johnson & Johnson is to buy women's health company FemRx for around $22 million in cash. The move will boost J&J's women's health business, which makes products for the treatment of a diversified range of gynaecological and urological disorders. FemRx has had a difficult year, beginning with job cuts and, more recently, the threat of delisting from the Nasdaq national market.